Search results
GenFleet receives China NMPA approval for Phase I/II solid tumour trial
Clinical Trials Arena via Yahoo Finance· 4 days ago"GenFleet receives China NMPA approval for Phase I/II solid tumour trial" was originally created and...
Groundbreaking cancer treatment may trigger more cancer – but here’s why you shouldn’t worry
The Conversation· 4 days agoIn the last few decades, scientists have finally learned to harness the immune system to successfully treat cancer. Car-T therapy, short for “chimeric antigen receptor T-cell ...
NGS: the road to personalising cancer care
Medical Device Network via Yahoo Finance· 4 days ago“This is a powerful new technology,” Baehner says. “Today it's reimbursed in colorectal cancer, but I think this is a technology that will be broadly...
Caris Life Sciences, Juniper Biologics Expand Solid Tumor Profiling Distribution Deal
GenomeWeb News· 2 hours agoThe deal expands the previous agreement, granting Juniper exclusive distribution rights throughout Africa and the Middle East.
New immunotherapy shows promise for advanced colorectal cancer in early trial
MedicalNewsToday via AOL· 4 days agoA combination of two monoclonal antibodies was effective in 61% of people with the most common form...
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
Clinical Trials Arena via Yahoo Finance· 5 days agoII ZN-c3-005 (DENALI) trial to treat platinum-resistant ovarian cancer (PROC) and the Phase II...
Kura Oncology Inc (KURA)
Morningstar· 5 days agoKura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors ...
Council Post: How Multi-Omics Is Empowering The Discovery Of Cancer Biomarkers
Forbes· 6 days agoDemaris Mills is president at Integrated DNA Technologies, a global genomics solutions provider....
Charles River (CRL) Advances in T-Cell Therapy With New Alliance
Zacks via Yahoo Finance· 6 days agoCharles River (CRL) and Captain T Cell announced an agreement on plasmid DNA and retrovirus vector...
...in a Phase I/II Clinical Trial Treating Advanced Solid Tumor Patients with KRAS G12D Mutation
Tehachapi News· 5 days agoG12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet.